Meropenem Dosing for eGFR 19 mL/min/1.73 m²
For a patient with an eGFR of 19 mL/min/1.73 m², administer one-half the recommended dose (250 mg for skin/soft tissue infections or 500 mg for intra-abdominal infections) every 12 hours. 1
FDA-Approved Dosing Algorithm
The FDA label provides clear guidance for renal dose adjustment based on creatinine clearance ranges 1:
- eGFR 10-25 mL/min (which includes your patient with eGFR 19): Give one-half the recommended dose every 12 hours
- This means:
- For complicated skin/soft tissue infections: 250 mg every 12 hours
- For intra-abdominal infections: 500 mg every 12 hours
- For Pseudomonas aeruginosa infections: 500 mg every 12 hours (half of the 1 gram standard dose)
Infusion Considerations
Administer as an intravenous infusion over 15-30 minutes 1. While the FDA label allows for bolus injection in patients with normal renal function, the infusion method is preferred in renal impairment.
Supporting Pharmacokinetic Evidence
The dosing recommendation is supported by pharmacokinetic studies showing that meropenem clearance correlates linearly with renal function 2. In patients with eGFR 5-29 mL/min/1.73 m², total clearance decreases to approximately 53 mL/min/1.73 m² compared to 186 mL/min/1.73 m² in normal renal function, and the terminal half-life extends from 0.9 hours to 6.8 hours 2.
Recent population pharmacokinetic modeling confirms that eGFR is the most significant covariate affecting meropenem clearance 3, 4, 5. For patients with severe renal impairment not on dialysis, a regimen of 0.5 g every 8 hours with 1-hour infusion has been suggested by some studies 3, though this exceeds FDA-approved dosing and should only be considered with therapeutic drug monitoring.
Critical Pitfalls to Avoid
- Do not use the standard every-8-hour dosing interval at this level of renal function—accumulation will occur and increase seizure risk 1
- Monitor for CNS adverse effects (seizures, confusion) as meropenem accumulation in renal impairment increases neurotoxicity risk 1
- Avoid concurrent valproic acid as meropenem significantly reduces valproic acid levels, increasing breakthrough seizure risk 1
- Consider therapeutic drug monitoring if available, particularly for critically ill patients or those with fluctuating renal function, as recent evidence shows weak correlation between eGFR estimates and actual meropenem clearance in complex patients 6
Special Considerations for Dialysis
If this patient progresses to hemodialysis (eGFR <10 mL/min), the dose remains one-half the recommended dose every 24 hours, with supplemental dosing after dialysis sessions as meropenem is readily dialyzable 1, 2.